TT
Therapeutic Areas
Authera Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AuT-1 | Exudative eye diseases (e.g., wet AMD, diabetic macular edema) | Pre-clinical |
| Undisclosed Pipeline | Not Specified (FcRn biology-based) | Pre-clinical |
Leadership Team at Authera
SM
Simone Mester
CEO & Co-founder
HP
Hans Petter Tjeldflaat
CFO
GC
Gaia Calamera
Lead Senior Scientist
MA
Milena A. Blaga
Senior Scientist
JS
Jenny Skjermo Telstad
Associate Scientist
JT
Jan Terje Andersen
Chairman of the Board & Co-founder
IS
Inger Sandlie
Board Member & Co-founder
ES
Eirik Sundlisæter
Medical Advisor